Robert W. Baird initiated coverage on TransMedics Group
$TMDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Robert W. Baird initiated coverage of TransMedics Group with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $116.00 → $75.00 | Overweight → Neutral | Analyst |
| 11/22/2024 | Buy → Hold | Needham | |
| 10/29/2024 | $200.00 → $125.00 | Outperform | Oppenheimer |
| 10/29/2024 | $208.00 → $109.00 | Buy | Needham |
| 9/24/2024 | $200.00 | Outperform | Robert W. Baird |
| 8/21/2024 | $208.00 | Buy | Needham |
| 6/6/2024 | $161.00 | Overweight | Cantor Fitzgerald |
| 6/4/2024 | $151.00 | Overweight | Stephens |
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
Analyst downgraded TransMedics Group from Overweight to Neutral and set a new price target of $75.00 from $116.00 previously
Needham downgraded TransMedics Group from Buy to Hold
Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously